The company was involved in a 2014 congressional inquiry about the rising price of doxycycline hyclate initiated by Elijah Cummings and Bernie Sanders.
[1] In December 2016, it was accused of conspiracy to raise the price of the antibiotic doxycycline and diabetes drug glyburide in 20 US states after investigations by Connecticut's Attorney General.
In June 2019, Heritage entered into a deferred prosecution agreement with the United States Department of Justice, Antitrust Division ("DOJ") relating to a one-count Information for a pricing conspiracy involving glyburide.
The US Department of Justice also brought criminal charges against former Chief Executive Officer Jeffrey Glazer and former Vice President of Commercial Operations Jason Malek for price fixing.
[3] On October 31, 2024, Heritage Pharmaceuticals and Apotex agreed to pay $49.1 million to resolve allegations of price-fixing in collusion to artificially raise drug prices as charged by a coalition of 50 state attorneys general.